Fimasartan
- Generic Name
- Fimasartan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31N7OS
- CAS Number
- 247257-48-3
- Unique Ingredient Identifier
- P58222188P
- Background
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals.
- Indication
Used for the treatment of hypertension and heart failure .
- Associated Conditions
- Hypertension, Essential Hypertension
- Associated Therapies
- -
Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT02397590
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients
- Conditions
- Diabetes MellitusHypertension
- Interventions
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT02312375
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaarยฎ (Losartan) in Adult Patients With Grade I-II Arterial Hypertension
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 179
- Registration Number
- NCT02248961
- Locations
- ๐ท๐บ
Moscow Health Department "City Clinical Hospital โ 81", Moscow, Russian Federation
๐ท๐บSt. Petersburg State healthcare Institution "City Hospital number 28" "Maximilianovskaya", St. Petersburg, Russian Federation
๐ท๐บSt. Petersburg State Healthcare Institution 'Diagnostic Centre #85', St. Petersburg, Russian Federation
A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 103
- Registration Number
- NCT02222480
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 86
- Registration Number
- NCT02205151
- Locations
- ๐ฐ๐ท
The Catholic university St. Mary hospital, Seoul, Korea, Republic of
to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 81
- Registration Number
- NCT02205190
- Locations
- ๐ฐ๐ท
Kyungpook National University Hospital, Daegu, Korea, Republic of
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
- Conditions
- Essential Hypertension, Dyslipidemia
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT02166814
- Locations
- ๐ฐ๐ท
The Catholic university St. Mary hospital, Seoul, Korea, Republic of
๐ฐ๐ทSeoul university Bundang hospital, Bundang, Korea, Republic of
๐ฐ๐ทChungNam university hospital, ChungNam, Korea, Republic of
Fimasartan/Amlodipine Combination Phase III
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 143
- Registration Number
- NCT02152306
- Locations
- ๐ฐ๐ท
Seoul National University Bundang Hospital, Bundang, Gyeonggi, Korea, Republic of
Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion
- Conditions
- Hypertension
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT02022774
- Locations
- ๐ฐ๐ท
Jeonju Jesus Hospital, Jeonju, Korea, Republic of
๐ฐ๐ทChonnam National University Hospital, Gwangju, Korea, Republic of
๐ฐ๐ทWonkwang University Hospital, Iksan, Korea, Republic of
To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT01921946
- Locations
- ๐ฐ๐ท
Kyungpook National University Hospital, Daegu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.